Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Butowski

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Biorxiv : the Preprint Server for Biology|March 31, 2025
IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastomaJacob S Young, Nam Woo Cho, Calixto-Hope G Lucas, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
JAMA Oncology|October 29, 2020
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical TrialTimothy F Cloughesy, Kevin Petrecca, Tobias Walbert, et al.
Acta Neuropathologica|September 6, 2020
The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paragangliomaBiswarathan Ramani, Rohit Gupta, Jasper Wu, et al.
Acta Neuropathologica|September 10, 2018
The genetic landscape of gliomas arising after therapeutic radiationGiselle Y López, Jessica Van Ziffle, Courtney Onodera, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Neuro-Oncology|April 29, 2017
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapyCassie N Kline, Nancy M Joseph, James P Grenert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Central nervous system cancersSteven S Brem, Philip J Bierman, Henry Brem, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Biorxiv : the Preprint Server for Biology|March 31, 2025
IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastomaJacob S Young, Nam Woo Cho, Calixto-Hope G Lucas, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
JAMA Oncology|October 29, 2020
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical TrialTimothy F Cloughesy, Kevin Petrecca, Tobias Walbert, et al.
Acta Neuropathologica|September 6, 2020
The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paragangliomaBiswarathan Ramani, Rohit Gupta, Jasper Wu, et al.
Acta Neuropathologica|September 10, 2018
The genetic landscape of gliomas arising after therapeutic radiationGiselle Y López, Jessica Van Ziffle, Courtney Onodera, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Neuro-Oncology|April 29, 2017
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapyCassie N Kline, Nancy M Joseph, James P Grenert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Central nervous system cancersSteven S Brem, Philip J Bierman, Henry Brem, et al.
Pageof 10